CustomSurg secures Seed round investment for AI-guided trauma surgery
18.03.2024
CustomSurg has closed its Seed round funding which will support key milestones over the next 2 years, including FDA submission and US market entry, to revolutionize trauma surgery with powered predictive analytics.
 CustomSurg's team
|
 |
CustomSurg, a frontrunner in AI-guided trauma surgery solutions, has successfully closed its Seed round of funding led by CHMBR Partners LLC, with backing from renowned international investors like HTGF (High-Tech Gründerfonds) and kickfund. This significant investment, coming at a crucial pre-FDA-approval stage of the company, signals confidence in CustomSurg's innovative approach.
The funding infusion is earmarked to drive CustomSurg through key milestones, spanning FDA submission, first-in-man study, US market entry, clinical research, and regulatory clearances. With this support, CustomSurg aims to redefine trauma surgery by integrating AI-powered predictive analytics into surgical procedures, promising improved outcomes and streamlined workflows.
CustomSurg participated in Venture Leaders Medtech and won the last stage of Venture Kick in 2021.
CustomSurg's team
The funding infusion is earmarked to drive CustomSurg through key milestones, spanning FDA submission, first-in-man study, US market entry, clinical research, and regulatory clearances. With this support, CustomSurg aims to redefine trauma surgery by integrating AI-powered predictive analytics into surgical procedures, promising improved outcomes and streamlined workflows.
CustomSurg participated in Venture Leaders Medtech and won the last stage of Venture Kick in 2021.
"Venture Kick was absolutely essential for us to bridge the time between research and grant-based funding and equity financing."
Valentin Christian Splett, Co-Founder & Co-CEO
Valentin Christian Splett, Co-Founder & Co-CEO
CustomSurg's team